Difficulty: Medium
Average Score: 81%
Practice
Which of the following drugs increases the metabolism of bishydroxycoumarin by induction of hepatic microsomal enzymes?
Correct answer
D
Rationale
The correct answer is D) Amrinone. Amrinone is a phosphodiesterase inhibitor that increases the metabolism of bishydroxycoumarin by inducing hepatic microsomal enzymes. This drug interaction is crucial to understand in pharmacology because it can affect the therapeutic efficacy of bishydroxycoumarin, which is a coumarin anticoagulant commonly known as warfarin.
A) Digoxin is a cardiac glycoside used to treat heart conditions by increasing myocardial contractility but does not have a significant impact on bishydroxycoumarin metabolism.
B) Furosemide is a loop diuretic that acts on the kidneys to increase urine production and does not influence hepatic microsomal enzyme induction to affect bishydroxycoumarin metabolism.
C) Enalapril is an angiotensin-converting enzyme (ACE) inhibitor used to manage hypertension and heart failure, but it does not have a direct effect on the metabolism of bishydroxycoumarin.
Understanding drug interactions and how medications can affect each other's metabolism is crucial in clinical practice to prevent potential adverse effects or therapeutic failures. Healthcare professionals need to be aware of these interactions to provide safe and effective patient care.
A) Digoxin is a cardiac glycoside used to treat heart conditions by increasing myocardial contractility but does not have a significant impact on bishydroxycoumarin metabolism.
B) Furosemide is a loop diuretic that acts on the kidneys to increase urine production and does not influence hepatic microsomal enzyme induction to affect bishydroxycoumarin metabolism.
C) Enalapril is an angiotensin-converting enzyme (ACE) inhibitor used to manage hypertension and heart failure, but it does not have a direct effect on the metabolism of bishydroxycoumarin.
Understanding drug interactions and how medications can affect each other's metabolism is crucial in clinical practice to prevent potential adverse effects or therapeutic failures. Healthcare professionals need to be aware of these interactions to provide safe and effective patient care.